WEIGAO GROUP (01066) announced that for the three months ended March 31, 2026, the company achieved unaudited revenue of approximately RMB 33.5 billion, representing a year-on-year increase of approximately 5.3%. During the period, the General Medical Devices and Pharmaceutical Packaging segments recorded relatively faster revenue growth. The Orthopedics and Intervention segments saw modest growth, while the Blood Management business experienced a decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.